resistance reveals serious, worldwide threat to public health. (2014). Available at: http://www.who.int/mediacentre/news/releases /2014/amr-report/en/.
[2] Salmond, G. P. C. & Fineran, P. C. A century of the phage: past, present and future. Nature reviews. Microbiology 13, 777–786 (2015).
[3] Haaber J, Leisner J. J., Cohn M.T., Catalan-Moreno A., Nielsen J.B., & Westh H. Bacterial viruses enable their host to acquire antibiotic resistance genes from neighbouring cells. Nat. Commun. 7, (2016).
[4] Czaplewski L., Bax R., Clokie M., Dawson M., Fairhead H., & Fischetti V.A. Alternatives to antibiotics-a pipeline portfolio review. Lancet. Infect. Dis. 16, 239–251 (2016).
[5] Keen, E. C. A century of phage research: bacteriophages and the shaping of modern biology. Bioessays 37, 6–9 (2015).
[6] Sulakvelidze, A., Alavidze, Z. & Morris, J. G. J. Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649–659 (2001).
[7] Wang, X. & Wood, T. K. Cryptic prophages as targets for drug development. Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 27, 30–38 (2016).
[8] Kutter, E. & Sulakvelidze, A. Bacteriophages: biology and applications. (Crc press, 2004).
[9] Alanis, A. J. Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. 36, 697–705 (2005).
[10] Viertel, T. M., Ritter, K. & Horz, H.-P. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J. Antimicrob. Chemother. 69, 2326–2336 (2014).
[11] Nanda, A. M., Thormann, K. & Frunzke, J. Impact of spontaneous prophage induction on the fitness of bacterial populations and host-microbe interactions. J. Bacteriol. 197, 410–419 (2015).
[12] Lang, A. S., Zhaxybayeva, O. and Beatty, J. T. Gene transfer agents: phage-like elements of genetic exchange. Nat. Rev. Microbiol. 10, 472–482 (2012).
[13] Soucy, S. M., Huang, J. & Gogarten, J. P. Horizontal gene transfer: building the web of life. Nat. Rev. Genet. 16, 472–482 (2015).
[14] Rostøl, J. T. & Marraffini, L. (Ph)ighting Phages: How Bacteria Resist Their Parasites. Cell Host Microbe 25, 184–194 (2019).
[15] Koskella, B. & Brockhurst, M. A. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol. Rev. 38, 916–931 (2014).
[16] Wittebole, X., De Roock, S. & Opal, S. M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5, 226–235 (2014).
[17] Fokine, A. & Rossmann, M. G. Molecular architecture of tailed double-stranded DNA phages. Bacteriophage 4, e28281 (2014).
[18] Cisek, A. A., Dąbrowska, I., Gregorczyk, K. P. & Wyżewski, Z. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages. Curr. Microbiol. 74, 277–283 (2017).
[19] Nayak, T., Rakesh K., Singh R., Jaiswal A., Gupta, & Gupta A T. BACTERIOPHAGE ENCODED ENDOLYSINS AS POTENTIAL ANTIBACTERIALS. 63, 39–48 (2019).
[20] Harper, D. R., Parracho H. M. R. T., Walker J., Sharp R., Hughes G., & Werthén M. Bacteriophages and Biofilms. Antibiotics 3, 270–284 (2014).
[21] Matsuzaki, S., Rashel M., Uchiyama J., Sakurai S., Ujihara T., & Kuroda M. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. Off. J. Japan Soc. Chemother. 11, 211–219 (2005).
[22] Lin, D. M., Koskella, B. & Lin, H. C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 8, 162–173 (2017).
[23] Clark, J. R. Bacteriophage therapy: history and future prospects. Future Virol. 10, 449–461 (2015).
[24] Rakonjac, J., Bennett, N. J., Spagnuolo, J., Gagic, D. & Russel, M. Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr. Issues Mol. Biol. 13, 51–76 (2011).
[25] Chan, B. K., Abedon, S. T. & Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769–783 (2013).
[26] Weber-Dabrowska, B., Mulczyk, M. & Górski, A. Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch. Immunol. Ther. Exp. (Warsz). 48, 547–551 (2000).
[27] Abedon, S. T. & Thomas-Abedon, C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11, 28–47 (2010).
[28] Romero-Calle, D., Guimarães Benevides, R., Góes-Neto, A. & Billington, C. Bacteriophages as Alternatives to Antibiotics in Clinical Care. Antibiot. (Basel, Switzerland) 8, (2019).
[29] Abedon, S. T. Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals (Basel). 8, 525–558 (2015).
[30] Sarker, S.A., Sultana S., Reuteler G., Moine D., Descombes P., & Charton F. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine 4, 124–137 (2016).
[31] Tetz, G. & Tetz, V. Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model. Gut Pathog. 8, 33 (2016).
[32] Parasion, S., Kwiatek, M., Gryko, R., Mizak, L. & Malm, A. Bacteriophages as an alternative strategy for fighting biofilm development. Polish J. Microbiol. 63, 137–145 (2014).
[33] Schmelcher, M. & Loessner, M. J. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage 4, e28137 (2014).
[34] Lerminiaux, N. A. & Cameron, A. D. S. Horizontal transfer of antibiotic resistance genes in clinical environments. Can. J. Microbiol. 65, 34–44 (2019).
[35] Chen, J. & Novick, R. P. Phage-mediated intergeneric transfer of toxin genes. Science 323, 139–141 (2009).
[36] Sybesma, W., Rohde C., Bardy P., Pirnay J-P., Cooper I., & Caplin J. Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II. Antibiot. (Basel, Switzerland) 7, (2018).
[37] Thiel, K. Old dogma, new tricks--21st Century phage therapy. Nat. Biotechnol. 22, 31–36 (2004).
[38] Sillankorva, S., Neubauer, P. & Azeredo, J. Isolation and characterization of a T7-like lytic phage for Pseudomonas fluorescens. BMC Biotechnol. 8, 80 (2008).
[39] Zaczek-Moczydłowska, M. A.,Young, G. K., Trudgett, J., Plahe, C.,Fleming, C. C., Campbell, K., & O’ Hanlon, R. Phage cocktail containing Podoviridae and Myoviridae bacteriophages inhibits the growth of Pectobacterium spp. under in vitro and in vivo conditions. PLoS One 15, e0230842 (2020).
[40] James, S. L., Rabiey, M., Neuman, B. W., Percival, G. & Jackson, R. W. Isolation, Characterisation and Experimental Evolution of Phage that Infect the Horse Chestnut Tree Pathogen, Pseudomonas syringae pv. aesculi. Curr. Microbiol. 77, 1438–1447 (2020).
[41] Ramírez, M., Neuman, B. W. & Ramírez, C. A. Bacteriophages as promising agents for the biological control of Moko disease (Ralstonia solanacearum) of banana. Biol. Control 149, 104238 (2020).
[42] Tanaka, C., Yamada K., Takeuchi H., Inokuchi Y., Kashiwagi A., & Toba T. A Lytic Bacteriophage for Controlling Pseudomonas lactis in Raw Cow’s Milk. Appl. Environ. Microbiol. 84, (2018).
[43] Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe 25, 219–232 (2019).
[44] Petrovic Fabijan, A., Lin R. C. Y., Ho J., Maddocks S., Ben Zakour N. L., & Iredell J. R. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat. Microbiol. 5, 465–472 (2020).
)
